1
Portions of Exhibit 10.5 have been redacted and are the subject of a
confidential treatment request filed with the Secretary of the Securities and
Exchange Commission.
2
May 31, 1999
OSI PHARMACEUTICALS, INC.
and
NOVARTIS PHARMA AG
AMENDMENT NO. 2 TO COLLABORATIVE AGREEMENT
3
Amendment No. 2
THIS AMENDMENT is made as of the 31st day of May, 1999 between NOVARTIS
PHARMA AG, successor-in-interest to the pharmaceutical business of CIBA-GEIGY
LIMITED, of Lichtstrasse 35, CH-4002 Basel, Switzerland (hereinafter referred to
as "NOVARTIS") and OSI PHARMACEUTICALS, INC., formerly known as ONCOGENE
SCIENCE, INC., of 106 Charles Lindbergh Boulevard, Uniondale, New York
11553-3649, USA (hereinafter referred to as "OSI").
WHEREAS, NOVARTIS and OSI are partners in a Collaborative Agreement dated
as of April 19, 1995 (the "1995 Agreement"), pursuant to which OSI granted to
NOVARTIS an exclusive license with the right to grant sublicenses to
manufacture, have manufactured, use and sell products containing the Compound
(as defined in Clause 1.3 of the 1995 Agreement) for the Licensed Indications
(as defined in Clause 1.5 of the 1995 Agreement) (all capitalized items used
herein but not defined shall have the meanings described thereto in the 1995
Agreement); and
WHEREAS, pursuant to the 1995 Agreement, OSI also granted to NOVARTIS an
option to acquire from OSI a license to manufacture, use and sell products
containing TGF-(beta)3 and other TGF-(beta)s for all other indications not now
included in the Licensed Indications; and
WHEREAS, the four year time limit to exercise the option was extended
until May 31, 1999 by an amendment to the 1995 Agreement ("Amendment 1") dated
April 13, 1999; and
WHEREAS, OSI and NOVARTIS hereby wish to amend certain terms of the 1995
Agreement.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
1. References. All references in the 1995 Agreement to "CIBA-GEIGY" or "CG"
shall be deemed to be references to "NOVARTIS". All references in the 1995
Agreement to "ONCOGENE SCIENCE" shall be deemed to be references to "OSI".
2. Recitals. The recital (F) in the 1995 Agreement shall be deleted in its
entirety and replaced with the following:
"NOVARTIS also wishes to have the opportunity to acquire from OSI a
license to manufacture, use and sell products containing TGF-(beta)3 and
other TGF-(beta)s for certain other indications not now included in the
Licensed Indications".
4
3. Definitions.
(a) Section 1.5 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"1.5 "Licensed Indications" shall mean: (i) bone, cartilage and
tendon repair, and (ii) additional indications deemed to be
included in the Licensed Indications pursuant to Clause 5.7
and Clause 5.8, as amended."
(b) Section 1.7 of the 1995 Agreement shall be amended so that the
language immediately following subsection (v) shall be as follows:
"all to the extent actually allowed, accrued or taken, and as
determined in accordance with the standard accounting
procedures of the party (i.e., NOVARTIS or OSI) making the Net
Sales."
(c) Section 1.11 of the 1995 Agreement shall be amended as follows:
"1.11 "Products" shall mean pharmaceutical preparations containing
the Compound designed for administration to human beings and
animals which fall within the scope of the claims of the OSI
Patents."
4. Supply of TGF-(beta)s.
(a) The second sentence of Section 3.3(d) of the 1995 Agreement shall be
deleted and replaced with the following:
"3.3(d) It is understood that NOVARTIS (i) shall not be obliged to
scale up its manufacturing process solely to meet the
requirements of OSI and OSI's licensees for research and
development purposes and clinical trials, and (ii) shall only
be obliged to supply Compound to OSI and OSI's licensees for
such purposes as long as it has sufficient Compound for its
own consumption. Provided NOVARTIS decides to initiate full
development of a Product in the Licensed Indications, it is
the intention of NOVARTIS to scale up such process to meet its
estimated future requirements. NOVARTIS will use commercially
reasonable efforts in designing its processing capacity so
that it is adequate to also meet all of OSI's requirements and
that of OSI's licensees for commercial quantities of the
Compound foreseen at the time of such scale up. If such
processing capacity proves to be adequate, NOVARTIS shall use
reasonable efforts to also supply OSI and the licensees of
OSI."
(b) The third sentence of Section 3.3(d) of the 1995 Agreement shall be
deleted and replaced with the following:
5
"3.3(d) Should NOVARTIS fail to do so, or if processing capacity
should prove to be inadequate to meet all OSI actual
requirements and NOVARTIS should be unwilling to invest in
additional capacity, or if NOVARTIS decides not to initiate
full development of a Product, it agrees if so requested to
grant a license to OSI under the NOVARTIS Patents and NOVARTIS
Know-How to produce the Compound on terms to be negotiated in
good faith, the financial terms to be reasonable having regard
to the cost of supplies of the Compound as at the date of the
license negotiations, the cost to OSI of procuring the grant
of licenses for any parts of the process covered by Third
Party Patents, and the estimated production costs of OSI."
(c) At the end of Section 3.3(e) of the 1995 Agreement the following
language shall be added:
"3.3(e) The parties furthermore agree that in case NOVARTIS decides
not to continue the development of the Compound in the
Licensed Indications NOVARTIS shall, upon the request of OSI,
make available its remaining stock of Compound in accordance
with the arrangements hereinafter, whereupon NOVARTIS shall no
longer be required to produce further Compound for supply to
OSI and OSI's licensees."
(d) The second sentence of Section 3.3(f) of the 1995 Agreement shall be
deleted and replaced with the following:
"3.3(f) Except during the 36-month notification periods or in case of
the discontinuance of the development of the Compound in the
Licensed Indications as set forth in Sections 3.3(b) and
3.3(e), NOVARTIS shall, in the event that it is unable to
supply the Compound to OSI for a period of 90 days by reason
of force majeure or otherwise, use commercially reasonable
endeavours to have an alternative plant for the production of
the Compound validated within one year from the date of
cessation of supply."
5. Development.
(a) Section 4.1 of the 1995 Agreement (including subsections 4.1.1, 4.1.2,
4.1.3 and 4.1.4) shall be deleted in its entirety and replaced with the
following:
"4.1 NOVARTIS shall be solely responsible, at its own expense, for
the development of the Products for the Licensed Indications.
NOVARTIS shall use reasonable diligence to take all steps
necessary for the development of such Products."
6
(b) The following language shall be added after Section 4.3 of the 1995
Agreement, Section 4.3 then becoming Section 4.3.1:
4.3.2 NOVARTIS hereby acknowledges and notifies OSI that as of May
31, 1999 (the "Discontinuance Date"), NOVARTIS has
discontinued development of Products for the indications of
oral mucositis and healing of soft tissue wound, including
prevention of scarring and fibrosis (such indications being
hereinafter referred to as the "Discontinued Indications").
NOVARTIS and OSI agree that all licenses heretofore granted to
NOVARTIS with respect to the Discontinued Indications are
terminated. With respect to the Discontinued Indications, upon
and following the Discontinuance Date, NOVARTIS shall make
available to OSI, as more specifically described below, for
use by OSI and its licensees, the results of development work
carried out up to the Discontinuance Date, including, without
limitation, access to NOVARTIS' Investigational New Drug
("IND") filing made with the United States Food and Drug
Administration and any equivalent filings made in countries
other than the United States. It is understood that results
relating to formulation of the Compound and analytical methods
developed by NOVARTIS up to the Discontinuance Date shall be
excluded from such transfer. NOVARTIS shall make a good faith
effort to make available the results of NOVARTIS' development
work by delivery of all written materials to OSI within 45
days following the Discontinuance Date and by meeting for one
day with representatives of OSI and OSI's licensees at a place
and on a date mutually convenient within 45 days following the
receipt by NOVARTIS of an agenda of outstanding issues
necessary for OSI and/or OSI's licensees to continue work in
the Discontinued Indication. NOVARTIS hereby acknowledges and
agrees that OSI and/or OSI's licensees may use any of the
foregoing results for the purpose of continuing development
for indications other than the Licensed Indications subject to
the following terms and conditions:
(a) with respect to development and sales of a Product for
oral mucositis by OSI or a licensee of OSI, OSI shall pay to
NOVARTIS (i) ** of any Net Sales made directly by OSI, and/or
(ii) ** of any revenue received by OSI from its licensee(s)
including, without limitation, revenue generated by licensing
fees, milestone payments or royalties;
- ----------
** This portion has been redacted pursuant to a request for confidential
treatment.
7
(b) with respect to development and sales of a Product for any
indications other than oral mucositis or other than any
indication included within the Licensed Indications, OSI shall
pay to NOVARTIS (i) ** of any Net Sales made directly by OSI,
and/or (ii) ** of any revenue received by OSI from its
licensee(s), including, without limitation, revenue generated
by licensing fees, milestone payments or royalties; and
(c) with respect to any indications other than oral mucositis
or other than any indication included within the Licensed
Indications, if OSI or its licensee(s) completes Phase II
clinical trials with respect to a Product and, at such point,
seeks a licensee to complete development of the Product and to
commercialize the Product, OSI hereby grants to NOVARTIS a
right of first negotiation with respect to such a license. OSI
and NOVARTIS shall negotiate such a license in good faith
taking into consideration the contributions of the parties up
to the Discontinuance Date. If the parties fail to enter into
such a license, OSI or its licensee may enter into such a
license with a third party, provided that OSI or its licensee
may not offer more favorable terms to a third party without
first offering such favorable terms to NOVARTIS.
(d) For the purpose of calculating the royalties Sections 5.2
and 5.3 shall be applicable and Sections 5.4, 5.5 and 5.6
shall apply to all payments made by OSI hereunder."
(c) Section 4.5 of the 1995 Agreement shall be deleted in its entirety.
6. Payment of Royalties and for Rights Granted.
(a) Section 5.2 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.2 NOVARTIS agrees to pay OSI a royalty of ** of Net Sales of the
Products in the Licensed Indications made by NOVARTIS or its
sub-licensees during the royalty period. OSI agrees to pay
NOVARTIS a royalty of ** of Net Sales made directly by OSI of
the Products outside the Licensed Indications in accordance
with Section 4.3.2 during the royalty period. The royalty
period shall be calculated on a country-by-country basis and
shall commence on the date of the commercial launch of any of
the Products either by NOVARTIS and/or OSI, as applicable, and
shall end on the date of expiry of the Patents in the
country."
- ----------
** This portion has been redacted pursuant to a request for confidential
treatment.
8
(b) Section 5.3 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.3 If OSI shall not have applied for any Patent in a particular
country or if patent protection for a Product sold either by
NOVARTIS and/or OSI, as applicable, is refused or revoked, the
rate of royalty payable on Net Sales in that country shall be
reduced **. Royalties under this Section 5.3 shall be payable
for a period of ten years from the date of commercial launch
in the country in question."
(c) Section 5.4 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.4 No later than 60 days after the end of each Half Year NOVARTIS
and/or OSI shall deliver to the other party a statement
showing its and its (sub)licencees' Net Sales of Products
invoiced during such Half Year, and in the case of OSI also
any revenue from its licencee(s) and shall pay to the other
party the amount due on such Net Sales and/or revenue, as
applicable."
(d) Section 5.5 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.5 NOVARTIS and OSI shall keep accurate records in sufficient
detail to enable the amount of payments due hereunder to be
calculated and shall maintain such records for a period of two
Years after the end of the period to which they relate.
NOVARTIS and OSI shall be entitled to have such records
examined during normal working hours by an independent firm of
accountants to which the other party has no reasonable
objection so as to verify the correctness of any payment
PROVIDED HOWEVER that such firm of accountants shall only
report to the other party the correct amount of Net Sales and
the amount of royalty due and in the case of OSI any revenue
from licencee(s), and shall keep confidential all other
information acquired in the course of such examination."
- ----------
** This portion has been redacted pursuant to a request for confidential
treatment.
9
(e) Section 5.6 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.6 (a) Royalties and any other payments due hereunder shall be
made in US Dollars into such accounts as shall be nominated by
the receiving party for that purpose. In the case of NOVARTIS
Net Sales in currencies other than in US Dollars, such Net
Sales shall first be calculated in the foreign currency, then
converted to Swiss Francs and then converted to US Dollars, in
each case using a ** exchange rate calculated on the basis of
NOVARTIS' ** average exchange rates. NOVARTIS' monthly average
exchange rates are currently calculated using the average of
Reuters Daily Rates between 09:14 a.m. and 10:00 a.m. on the
one hand and the official Frankfurt fixing of the German
National Bank rates in the afternoon on the other hand. In the
case of OSI Net Sales or revenue in currencies other than US
Dollars, royalties and any other payments shall first be
calculated in the foreign currency and then converted to US
Dollars, in each case using for ** calculation the foreign
currency exchange rate published in The Wall Street Journal on
the last day of the preceding month.
(b) If NOVARTIS or OSI are obliged to deduct withholding tax
on any payments to be made hereunder, the payment shall be
made net of withholding tax. NOVARTIS and OSI, as applicable,
will deliver to the other party receipts or other evidence of
payment issued by the relevant tax authorities to enable it to
claim any available double taxation relief."
(f) The second sentence of Section 5.7 of the 1995 Agreement shall be
deleted in its entirety and replaced with the following:
"5.7 NOVARTIS is hereby granted an exclusive option to include the
treatment of transplant patients (e.g. graft protection), the
treatment of ischemia (e.g., angina pectoris and peripheral
vascular disease), the treatment of stroke patients, and the
treatment of inflammatory bowel disease as additional
indications and a nonexclusive option to include any other
additional indications relating to the Compound (other than
the Discontinued Indications and Licensed Indications) upon
making the milestone payment or stock purchase set forth in
Section 5.8, as amended, such option to be exercised, if at
all, within sixty (60) days of the decision by NOVARTIS to
initiate full development of the Product (i.e., Phase IIB or
Phase III clinical trials for bone, cartilage or tendon
repair, which decision shall be communicated promptly to OSI
in writing) or by May 31, 2003, whichever is earlier."
- ----------
** This portion has been redacted pursuant to a request for confidential
treatment.
10
(g) Section 5.8 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"5.8 Within sixty (60) days after the earlier of: (a) the date of
the decision by NOVARTIS to initiate full development (as
defined in Section 5.7) of a Product for bone, cartilage or
tendon repair, or (b) the exercise of the option set out in
Section 5.7, NOVARTIS agrees to either make a milestone
payment of ** in cash to OSI or to purchase ** of OSI common
stock at a per share price equal to ** of the average closing
price for the 30-day period ending on the date of purchase.
Upon making this milestone payment or completion of the stock
purchase, such additional indications relating to the Compound
shall be deemed to be included in the Licensed Indications.
The retention of the rights to such other indications shall be
subject to the provisions of the Stock Purchase Agreement."
7. Termination.
Section 9.4 of the 1995 Agreement shall be deleted in its entirety and
replaced with the following:
"9.4 Termination or expiry of this Agreement shall not affect the
rights of any party against the other party in respect of any
antecedent breach of the terms hereof, nor the rights or
obligations of any party pursuant to the provisions of Clauses
4 and 5 with regard to, in each instance, royalty obligations
in respect of the Net Sales and/or revenue from licensees up
to the date of termination or expiry, Clause 7 in respect of
confidentiality and Clause 10 in respect of indemnities."
8. Schedules.
Schedules 1 and 2 of the 1995 Agreement shall be deleted in their entirety
and replaced with the Schedules attached hereto.
9. Miscellaneous.
(a) Except as amended hereby, all terms and conditions of the 1995
Agreement shall remain in full force and effect.
- ----------
** This portion has been redacted pursuant to a request for confidential
treatment.
11
(b) This Amendment shall be construed and applied in accordance with the
laws of the State of New York.
(c) This Amendment shall be binding upon and shall inure to the benefit of
the parties hereto and their respective legal representatives, successors and
permitted assigns.
(d) This Amendment may be executed in two counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.
12
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed as of the date first above written.
OSI PHARMACEUTICALS, INC.
By: /s/
--------------------------------------------
Colin Goddard, Ph.D.
President & Chief Executive Officer
NOVARTIS PHARMA AG
By: /s/
--------------------------------------------
Gisela Schelling
Legal Counsel
Ivan Csendes, Ph.D.
Head Licensing Drug-Delivery & Out-Licensing
Business Development & Licensing
13
SCHEDULE 1
List of OSI Patents/Applications
Country Application/Patent No. Filing Date Expiry Date
- ------- ---------------------- ----------- -----------
Australia 600230 21.04.1986 21.04.2002
Australia 620795 19.10.1987 19.10.2003
Australia 668072 17.05.1990 17.05.2006
Australia 659415 25.06.1991 25.06.2007
Australia 657913 25.06.1991 25.06.2007
Australia 51628/93 21.09.1993 21.19.2009
Austria E83152 15.04.1986 15.04.2006
Austria 384494 (E) 20.10.1987 20.10.2007
Austria 536275 (E) 25.06.1991 25.06.2011
Belgium 200090 (E) 15.04.1986 15.04.2006
Belgium 384494 (E) 20.10.1987 20.10.2007
Belgium 536275 (E) 25.06.1991 25.06.2011
Canada 1274471 18.04.1986 18.04.2006
Canada 549582-2 20.10.1987 20.10.2007
Canada 2084510 25.06.1991 25.06.2011
Denmark 536275 (E) 25.06.1991 25.06.2011
EPO 200090 (E) 15.04.1986 15.04.2006
EPO 95109866.4 20.10.1987 20.10.2007
EPO 536275 (E) 25.06.1991 25.06.2011
France 200090 (E) 15.04.1986 15.04.2006
France 384494 (E) 20.10.1987 20.10.2007
France 536275 (E) 25.06.1991 25.06.2011
Germany P3637241.5-08 15.04.1986 15.04.2006
Germany 384494 (E) 20.10.1987 20.10.2007
Germany 536275 (E) 25.06.1991 25.06.2011
Greece 384494 (E) 20.10.1987 20.10.2007
Greece 536275 (E) 25.06.1991 25.06.2011
Ireland 60059 14.04.1986 14.04.2006
Ireland 2809/87 19.10.1987 19.10.2007
Israel 78546 20.04.1986 20.04.2006
Israel 84211 19.10.1987 19.10.2007
Israel (Div.) 103617 20.04.1986 20.04.2006
Italy 20732BE/93 15.04.1986 15.04.2006
Italy 384494 (E) 20.10.1987 20.10.2007
Italy 536275 (E) 25.06.1991 25.06.2011
Japan 2065324 18.04.1986
Japan 265201/87 20.10.1987
Japan 513051/91 25.06.1991
Liechtenstein 200090 (E) 15.04.1986 15.04.2006
Liechtenstein 384494 (E) 20.10.1987 20.10.2007
Liechtenstein 536275 (E) 25.06.1991 25.06.2011
Luxemborg 200090 (E) 15.04.1986 15.04.2006
14
Country Application/Patent No. Filing Date Expiry Date
- ------- ---------------------- ----------- -----------
Luxemborg 384494 (E) 20.10.1987 20.10.2007
Luxemborg 536275 (E) 25.06.1991 25.06.2001
Netherlands 200090 (E) 15.04.1986 15.04.2006
Netherlands 384494 (E) 20.10.1987 20.10.2007
Netherlands 536275 (E) 25.06.1991 25.06.2011
New Zealand 215887 18.04.1986 18.04.2002
New Zealand 222168 14.10.1987 14.10.2003
Spain 554177 18.04.1986 18.04.2006
Spain 8702981 19.10.1987 19.10.2007
Spain 536275 (E) 25.06.1991 25.06.2011
Sweden 384494 (E) 20.10.1987 20.10.2007
Sweden 536275 (E) 25.06.1991 25.06.2011
Switzerland 200090 (E) 15.04.1986 15.04.2006
Switzerland 384494 (E) 20.10.1987 20.10.2007
Switzerland 536275 (E) 25.06.1991 25.06.2011
United Kingdom 200090 (E) 15.04.1986 15.04.2006
United Kingdom 384494 (E) 20.10.1987 20.10.1987
United Kingdom 536275 (E) 25.06.1991 25.06.2011
USA 5262319 25.06.1990 16.11.2010
USA 08/118197 19.04.1985*
USA 08/2940641 19.04.1985*
USA 5817625 21.09.1992 06.10.2015
USA 5635489 21.09.1992 03.06.2014
USA 5821297 21.09.1992 20.10.2015
USA 5871724 21.09.1992 16.02.2016
USA 08/457097 19.04.1985
* Effective filing date
15
SCHEDULE 2
List of Novartis Patents
A. Case 4-17861
Country Application/Patent No. Filing Date Expiry Date
- --------------------------------------------------------------------------------
Australia 638075 27.11.1990 27.11.2006
Austria 433225 (EP) 27.11.1990 27.11.2010
Belgium 433225 (EP) 27.11.1990 27.11.2010
Canada 2031430 04.12.1990 04.12.2010
Denmark 433225 (EP) 27.11.1990 27.11.2010
Finland 905956 03.12.1990 03.12.2010
France 433225 (EP) 27.11.1990 27.11.2010
Germany 433225 (EP) 27.11.1990 27.11.2010
Great Britain 89275465 06.12.1989 (priority
application;
now lapsed)
Great Britain 433225 (EP) 27.11.1990 27.11.2010
Greece 433225 (EP) 27.11.1990 27.11.2010
Hungary 8084/1990 05.12.1990 05.12.2010
Ireland 4386/90 05.12.1990 05.12.2010
Israel 96549 05.12.1990 05.12.2010
Italy 433225 (EP) 27.11.1990 27.11.2010
Japan 330871/90 30.11.1990
Korea 9881/90 05.12.1990
Luxembourg 433225 (EP) 27.11.1990 27.11.2010
Mexico 172600 04.12.1990 04.12.2010
Netherlands 433225 (EP) 27.11.1990 27.11.2010
New Zealand 236333 04.12.1990 04.12.1990
Norway 301768 05.12.1990 05.12.2010
Pakistan 132484 10.11.1990 06.12.2005
Philippines 41681 05.12.1990
Philippines 47025 05.12.1990
Philippines 48001 05.12.1990
Portugal 96068 04.12.1990
South Africa 9762/90 05.12.1990 05.12.2010
Spain 433225 (EP) 27.11.1990 27.11.2010
Sweden 433225 (EP) 27.11.1990 27.11.2010
Switzerland 433225 (EP) 27.11.1990 27.11.2010
Taiwan 56999NI 13.11.1990 11.06.2007
USA 621502/07 03.12.1990
USA 960309/07 (Cont.) 13.10.1992
USA 201703/08 (Cont. 2) 25.02.1994
USA 5650494 (Cont. 3) 07.06.1995 22.07.2014
USA 789588/08 (Cont. 3/Div) 24.01.1997
16
SCHEDULE 2 continued
B. Case 4-20038
Country Application/Patent No. Filing Date Expiry Date
- --------------------------------------------------------------------------------
Australia 690311 12.07.1995 12.07.2015
Austria 95926857.4 (EP) 12.07.1995 12.07.2015
Belgium 95926857.4 (EP) 12.07.1995 12.07.2015
Canada 2194582 12.07.1995 12.07.2015
Denmark 95926857.4 (EP) 12.07.1995 12.07.2015
Europe 95926857.4 (EP) 12.07.1995 12.07.2015
Europe 94810438.5 (EP) 25.07.1994 (priority
application;
lapsed)
Finland 970229 12.07.1995 12.07.2015
France 95926857.4 (EP) 12.07.1995 12.07.2015
Germany 95926857.4 (EP) 12.07.1995 12.07.2015
Great Britain 95926857.4 (EP) 12.07.1995 12.07.2015
Greece 95926857.4 (EP) 12.07.1995 12.07.2015
Hungary P9700210 12.07.1995 12.07.2015
Ireland 95926857.4 (EP) 12.07.1995 12.07.2015
Israel 114701 24.07.1995 24.07.2015
Italy 95926857.4 (EP) 12.07.1995 12.07.2015
Japan 505400/96 12.07.1995 12.07.2015
Korea-South 700476/97 12.07.1995 12.07.2015
Luxembourg 95926857.4 (EP) 12.07.1995 12.07.2015
Mexico 970656 12.07.1995 12.07.2015
Monaco 95926857.4 (EP) 12.07.1995 12.07.2015
Netherlands 95926857.4 (EP) 12.07.1995 12.07.2015
New Zealand 290373 12.07.1995 12.07.2015
Norway P970325 12.07.1995 12.07.2015
Pakistan 395/95 23.07.1995 23.07.2011
Philippines 50939 18.07.1995
Portugal 95926857.4 (EP) 12.07.1995 12.07.2015
Singapore 37588 12.07.1995 12.07.2015
South Africa 6138/95 24.07.1995 24.07.2015
Spain 95926857.4 (EP) 12.07.1995 12.07.2015
Sweden 95926857.4 (EP) 12.07.1995 12.07.2015
Switzerland 95926857.4 (EP) 12.07.1995 12.07.2015
Taiwan 84107188 11.07.1995 11.07.2015
USA 08/776445 12.07.1995 12.07.2015
USA 09/123233 (Cont.) 28.07.1998 24.01.2017
17
SCHEDULE 2 continued
C. Case 4-20039
Country Application/Patent No. Filing Date Expiry Date
- --------------------------------------------------------------------------------
Australia 699879 12.07.1995 12.07.2015
Austria 95926858.2 12.07.1995 12.07. 2015
Belgium 95926858.2 12.07.1995 12.07. 2015
Canada 2194578 12.07.1995 12.07. 2015
Denmark 95926858.2 12.07.1995 12.07. 2015
Europe 95926858.2 12.07.1995 12.07. 2015
Europe 94810439.3 25.07.1994 (priority
application;
lapsed)
Finland 970258 12.07.1995 12.07.2015
France 95926858.2 12.07.1995 12.07.2015
Germany 95926858.2 12.07.1995 12.07.2015
Great Britain 95926858.2 12.07.1995 12.07.2015
Greece 95926858.2 12.07.1995 12.07.2015
Hungary P9700211 12.07.1995 12.07.2015
Ireland 95926858.2 12.07.1995 12.07.2015
Israel 114702 24.07.1995 24.07.2015
Italy 95926858.2 12.07.1995 12.07.2015
Japan 505401/96 12.07.1995 12.07.2015
Korea-South 700477/97 12.07.1995 12.07.2015
Luxembourg 95926858.2 12.07.1995 12.07.2015
Mexico 970657 12.07.1995 12.07.2015
Monaco 95926858.2 12.07.1995 12.07.2015
Netherlands 95926858.2 12.07.1995 12.07.2015
New Zealand 290374 12.07.1995 12.07.2015
Norway P970326 12.07.1995 12.07.2015
Pakistan 396/95 23.07.1995 23.07.2011
Philippines 50956 19.07.1995
Portugal 95926858.2 12.07.1995 12.07.2015
Singapore 36546 12.07.1995 12.07.2015
South Africa 6139/95 24.07.1995 24.07.2015
Spain 95926858.2 12.07.1995 12.07.2015
Sweden 95926858.2 12.07.1995 12.07.2015
Switzerland 95926858.2 12.07.1995 12.07.2015
Taiwan 84107189 11.07.1995 11.07.2015
USA 08/776444 12.07.1995 12.07.2015